Bictegravir 1611493-60-7
Nkọwa
Bictegravir bụ akwụkwọ akụkọ, onye na-egbochi nje HIV-1 na IC50 nke 7.5 nM.
Na Vitro
Bictegravir (BIC) na-egbochi ọrụ mbufe eriri na IC50 nke 7.5± 0.3 nM. N'ihe metụtara mgbochi ya nke ọrụ mbufe strand, Bictegravir bụ ihe na-egbochi ike nke 3.'-Nhazi ọrụ nke HIV-1 IN, yana IC50 nke 241±51 nM. Bictegravir na-eme ka mkpokọta 2-LTR dị gburugburu ~ 5-n'ụzọ metụtara njikwa a na-akwa emo ma na-ebelata ọnụ ọgụgụ nke ngwaahịa njikọta nke ọma na sel ndị butere site na 100 okpukpu. Bictegravir na-egbochi nje HIV-1 nke ọma na mkpụrụ ndụ MT-2 na MT-4 nwere EC50s nke 1.5 na 2.4 nM, n'otu n'otu. Bictegravir na-egosipụta mmetụta antiviral siri ike na CD4+ T lymphocytes bụ isi na macrophages nke monocyte enwetara, yana EC50s nke 1.5.±0.3 nM na 6.6±4.1 nM, n'otu n'otu, nke tụnyere ụkpụrụ enwetara n'ahịrị T-cell[1].
MCE akwadobeghị izi ezi nke ụzọ ndị a. Ha bụ naanị maka ntụnye aka.
| Nọmba NCT | Onye nkwado | Ọnọdụ | Ụbọchị mmalite | Usoro |
| NCT03998176 | Mahadum Nebraska | Gilead Sciences | HIV-1 - ọrịa | Ọktoba 9, 2019 | Agba 4 |
| NCT03789968 | Thomas Jefferson University | Mahadum Maryland, College Park | Health University Indiana | Ụlọ Ọgwụ Ụlọ Ọgwụ Brooklyn | Mahadum Illinois na Chicago | Mahadum Nova Southeast | Mahadum California, San Francisco | HIV + AIDS | Septemba 1, 2019 | |
| NCT04249037 | Mahadum Colorado, Denver | Gilead Sciences | HIV + AIDS | Maachị 1, 2020 | Ọ metụtaghị |
| NCT04132674 | Ụlọ Ọrụ Ọrịa na-efe efe nke Vancouver | Nje Virus Immunodeficiency mmadụ nke mbụ | Ojiji ọgwụ | Nọvemba 26, 2018 | Agba 4 |
| NCT04054089 | Cristina Mussini | Mahadum nke Modena na Reggio Emilia | Ọrịa HIV | Septemba 2019 | Agba 4 |
| NCT04155554 | Azienda Ospedaliera Universitaria Senese|Katọlik University of the Sacred Heart|Ospedale Policlinico San Martino|Azienda Ospedaliera San Paolo|Ospedale Amedeo di Savoia | HIV-1 - ọrịa | Jenụwarị 29, 2020 | Nkeji 3 |
| NCT02275065 | Sayensị Gilead | Ọrịa HIV-1 | Ọktoba 2014 | Agba 1 |
| NCT03711253 | Mahadum Southern California | Ọrịa HIV dị oke njọ | Ọktoba 14, 2019 | Agba 4 |
| NCT02400307 | Sayensị Gilead | HIV | Eprel 17, 2015 | Agba 1 |
| NCT03499483 | Fenway Community Health | Mgbochi HIV | Jenụwarị 24, 2019 | Agba 4 |
| NCT03502005 | Midland Research Group, Inc.|Gilead Sciences | Nje Virus Immunodeficiency nke mmadụ | Maachị 1, 2018 | Agba 4 |
Ọdịdị chemical

Atụmatụ18Arụmọrụ ntule na-agbanwe agbanwe nke akwadoro4, na6oru ngo na-akwado.
Usoro njikwa ogo mba ụwa dị elu etinyela ntọala siri ike maka ire ahịa.
Nlekọta dị mma na-aga n'ihu na usoro ndụ nke ngwaahịa ahụ niile iji hụ na ịdị mma na mmetụta ọgwụgwọ.
Ndị otu Regulatory Affairs ndị ọkachamara na-akwado ịdịmma chọrọ n'oge ngwa na ndebanye aha.
Ahịrị nkwakọ ngwaahịa Korea Countec
Taiwan CVC ahịrị nkwakọ ngwaahịa
Line CAM Board nke Italy
Igwe na-agbakọ Fette German
Ihe nchọpụta mbadamba ihe ngosi nke Japan
Ụlọ njikwa DCS


